retigabine/ezogabine

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

EpilepsyEpilepsy, Partial

Phase 3

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

TerminatedNCT01668654

GlaxoSmithKlineEpilepsy

Start: 2012-09-04End: 2013-06-18Updated: 2020-10-30

Unknown Phase

Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

CompletedNCT01457989

GlaxoSmithKlineEpilepsy, Partial

Start: 2011-08-31End: 2011-08-31Updated: 2012-10-29

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

CompletedNCT01587339

GlaxoSmithKlineEpilepsy

Start: 2010-09-30End: 2011-07-31Updated: 2013-09-16